After a promising start, #biotech #IPOs all but fizzled out this year, but #LBPharmaceuticals is hoping that won't stymy its chances of completing a #Nasdaq listing.
After a long biotech IPO lull, LB Pharma chances its arm
After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.
buff.ly
September 9, 2025 at 10:30 AM
After a promising start, #biotech #IPOs all but fizzled out this year, but #LBPharmaceuticals is hoping that won't stymy its chances of completing a #Nasdaq listing.
LB Pharmaceuticals to Present at 25th Needham Conference: LB Pharmaceuticals (Nasdaq: LBRX) will present at the 25th Needham Virtual Healthcare Conference after its Apr 9, 2026 release; watch for… 👈 Read full analysis #LBPharmaceuticals #NeedhamConference #Healthcare #Pharmaceuticals #Investing
LB Pharmaceuticals to Present at 25th Needham Conference
LB Pharmaceuticals (Nasdaq: LBRX) will present at the 25th Needham Virtual Healthcare Conference after its Apr 9, 2026 release; watch for timeline disclosures and potential re-rating.
dlvr.it
April 9, 2026 at 8:35 PM
LB Pharmaceuticals to Present at 25th Needham Conference: LB Pharmaceuticals (Nasdaq: LBRX) will present at the 25th Needham Virtual Healthcare Conference after its Apr 9, 2026 release; watch for… 👈 Read full analysis #LBPharmaceuticals #NeedhamConference #Healthcare #Pharmaceuticals #Investing
LB Pharmaceuticals Presents LB-102 Cognitive Data: LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized… 👈 Read full analysis #LBPharmaceuticals #CognitiveData #DementiaResearch #StrokeSurvivors #ClinicalTrials
LB Pharmaceuticals Presents LB-102 Cognitive Data
LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized trials are the key catalyst.
dlvr.it
March 27, 2026 at 5:03 PM
LB Pharmaceuticals Presents LB-102 Cognitive Data: LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized… 👈 Read full analysis #LBPharmaceuticals #CognitiveData #DementiaResearch #StrokeSurvivors #ClinicalTrials
#PharmaPhorum #biotech #IPO #LBPharma #LBPharmaceuticals #Nasdaqlisting #biotechIPOs #USA #drugdevelopment #LB102 #antipsychoticdrug #amisulpride #centralnervoussystem #schizophrenia #Amisulpride #clinicaldevelopment #bipolardepression #PositiveandNegativeSyndromeScale #PANSS
zurl.co/oJUIU
zurl.co/oJUIU
After a long biotech IPO lull, LB Pharma chances its arm
After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.
pharmaphorum.com
September 16, 2025 at 8:11 AM
